Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.

Miron B, Handorf E, Zarrabi K, Zibelman MR, Anari F, Ghatalia P, Plimack ER, Geynisman DM. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors. Urol Oncol. 2022 10; 40(10):454.e9-454.e16.

View in: PubMed